PhaseRx, Inc. (PZRX) to Announce Earnings on Monday
PhaseRx (NASDAQ:PZRX) last issued its earnings results on Thursday, August 10th. The company reported ($0.30) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.09).
Shares of PhaseRx, Inc. (NASDAQ:PZRX) opened at $0.69 on Friday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 3.17 and a current ratio of 3.17. PhaseRx, Inc. has a 12-month low of $0.54 and a 12-month high of $3.30.
An institutional investor recently raised its position in PhaseRx stock. Vanguard Group Inc. grew its holdings in PhaseRx, Inc. (NASDAQ:PZRX) by 4.0% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 142,182 shares of the company’s stock after buying an additional 5,500 shares during the period. Vanguard Group Inc. owned 1.22% of PhaseRx worth $135,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 2.38% of the company’s stock.
Separately, Laidlaw cut shares of PhaseRx from a “buy” rating to a “neutral” rating in a research report on Friday, October 13th.
PhaseRx Company Profile
PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood.
Receive News & Ratings for PhaseRx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseRx Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.